Latest posts tagged with #ctcl on Bluesky
Lymphir™ (denileukin diftitox-cxdl) is now available for the treatment of R/R Stage I-III #CTCL after at least 1 prior systemic therapy. From @medicalprofref.bsky.social.
https://bit.ly/48EhSc1
#lymsm
Soligenix Reaches Key Enrollment Milestone in HyBryte Phase 3 Trial for Lymphoma Treatment #USA #Princeton #Soligenix #CTCL #HyBryte
Soligenix Reports Q3 2025 Financial Results and Major Developments in Clinical Trials #United_States #Princeton #Soligenix #CTCL #HyBryte
Now it is imperative to include CLIPI in the routine evaluation of advanced stages Mycosis Fungoides & Sézary syndrome; especially when considering for alloSCT #ctcl
ashpublications.org/blood/articl...
Soligenix Reaches Major Safety Milestone for HyBryte™ in Treating Cutaneous T-Cell Lymphoma #United_States #Princeton #Soligenix #CTCL #HyBryte
Soligenix Expands Medical Advisory Board for European CTCL Treatment Advancement #United_States #Princeton #Soligenix #CTCL #HyBryte
Rare Diseases and Their Long-Term Revenue Potential: What Innovators Need to Know #United_States #New_York #Soligenix #CTCL #HyBryte
Congratulations to Dr. Michael Girardi, recipient of the 2025 Translational Research Program Award from
@llsusa.bsky.social to support his research developing new treatments for T-cell #lymphoma. #CTCL
yalecancercenter.org/news-article...
@yaleschoolofmed.bsky.social
#MycosisFungoides #CTCL
Atypical intraepidermal lymphocytes tagging along the basal epidermis with halos. No spongiosis. This case really doesn’t need immunohistochemisry to confirm #classic 😉
#pathology
#dermpath
#bluepath
Promising Results from HyBryte™ Therapy Show 75% Success Rate in CTCL Patients #United_States #Princeton #Soligenix #CTCL #HyBryte
Our recent article shines a light on a rare disease – cutaneous T-cell lymphoma (CTCL). 🩸🔬
📖 Dive into the diagnosis & treatment of this malignancy, featuring insights from leading experts.
👉 buff.ly/sdBGvVG 👈
#CTCL #RareDisease #HemOnc #Lymphoma #LYMsm #CTSM #ImmunoOnc #BloodSky #HemeSky
Soligenix Reports Promising Accomplishments and Financial Insights for 2024 Year-End #United_States #Princeton #Soligenix #CTCL #HyBryte
The #MAVORIC trial led by Dr. Francine Foss demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with #CTCL, including those with more advanced disease.
pubmed.ncbi.nlm.nih.gov/39894454/
@yale-hematology.bsky.social @yaleschoolofmed.bsky.social
A fusion protein therapy may be an effective treatment option for cutaneous T-cell #lymphoma, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Read more: news.feinberg.northwestern.edu/2025/01/17/i... via @nufeinbergmed.bsky.social #CTCL #lymsm
Exciting Progress in Treatment of Early-Stage Cutaneous T-Cell Lymphoma with HyBryte™ #None #Soligenix #CTCL #HyBryte
Soligenix Launches Phase 3 Trial for HyBryte™ to Treat Cutaneous T-Cell Lymphoma #United_States #Princeton #Soligenix #CTCL #HyBryte™
It’s great to see new research on #CTCL. I have the Folliculotropic subtype of mycosis fungoides. Luckily, I have stayed in stage 1A since my diagnosis 3 years ago. But it is a frustrating and uncomfortable cancer. Hopefully this will add much needed data that can be used to develop treatments.
Exciting Updates on HyBryte™: Clinical Study Shows Improved Results After Treatments #United_States #HyBryte™_Treatment #Soligenix #CTCL #Princeton,_NJ